The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

CTRC  -  chymotrypsin C (caldecrin)

Homo sapiens

Synonyms: CLCR, Caldecrin, Chymotrypsin-C, ELA4
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of CTRC


High impact information on CTRC


Chemical compound and disease context of CTRC


Biological context of CTRC

  • Plasma concentrations (Cmax and AUC) of ciprofloxacin and its M1 and M2 metabolites were significantly increased in subjects with reduced Clcr values (Clcr < 60 mL/min/1.73 m2) compared with normal subjects (Clcr > 90 mL/min/1.73 m2) [13].
  • The aim of the present investigation was to test the efficacy of WBR in estimating bone mineralization rate (m) and to evaluate the influence of renal function (Clcr) and bone mass (forearm bone mineral content; BMC) on WBR [14].
  • Both the kaliuresis and the calciuresis during tau were tightly correlated with the natriuresis over the broad range of CLCR [15].
  • In the first study, in 10 patients, there was a 10-fold increase in Na excretion and a small rise in diuresis (V) and Clcr, which was accompanied by an increase in Cldig from 57.5 +/- 32, and 60.7 +/- 27.3 (duplicate measurements) to 103.9 +/- 55.4 (p less than 0.01) and 103.8 +/- 46.5 ml min-1 (p less than 0.01) [16].
  • Group 1 patients had an average CLR:CLCR ratio greater than 1 for both the parent compound and the metabolite, suggesting that net tubular secretion was still intact, despite a diminished glomerular filtration rate (CLCR = 24 ml.min-1.73 m-2).(ABSTRACT TRUNCATED AT 250 WORDS)[17]

Associations of CTRC with chemical compounds

  • There were no significant changes in Vss or t1/2 after multiple dosing, but there were significant correlations between CLCR and cefotaxime total body clearance, cefotaxime and desacetyl cefotaxime renal clearance, and cefotaxime nonrenal clearance [2].
  • Peak ceforanide levels (mean = 69 +/- 12 micrograms/ml) and volumes of distribution did not vary with creatinine clearance (Clcr, ml/min/1.73 m2) and both plasma clearance and renal clearance decreased linearly as Clcr decreased [18].
  • Correspondingly, urinary excretion decreased to 3.35 mg/24 hours and total body clearance to 7.8 L/h. In uraemic patients (CLCR less than 5 ml/min/1.73m2) the total clearance of bisoprolol was 5.0 L/h and the elimination half-life was 24.2 hours [19].
  • A positive correlation was observed between ciprofloxacin clearance (Cl) and Clcr with a slope of 0.29 (r2 = 0.78) and between renal clearance (Clr) and Clcr with a slope of 0.19 (r2 = 0.84) [13].
  • Renal clearance of pentamidine (Clr) decreased over time but always exceeded the Clcr, indicating tubular secretion [20].
  • In the high Ca(2+) environment of the duodenum, chymotrypsin C facilitates trypsinogen activation, whereas in the lower intestines, chymotrypsin C promotes trypsin degradation as a function of decreasing luminal Ca(2+) concentrations [21].

Analytical, diagnostic and therapeutic context of CTRC

  • BACKGROUND: The aim of this retrospective study is to assess the accuracy of single slice helical CT scan with intravenous, and rectal contrast (CTRC) in the diagnosis of acute appendicitis (AA) in patients with suspected AA, with particular analysis of the diagnostic signs [22].
  • METHODS: Oral omapatrilat, 10 mg/d, was administered for 8 to 9 days to three groups of eight subjects with varying degrees of renal function (CLCR values, normal > or = 80; mild to moderate impairment < 80 to > or = 30; severe impairment < 30 mL/min/1.73 mL2) and to six subjects undergoing maintenance hemodialysis [7].
  • The drug was administered by intravenous short time infusion in 12 CHD-patients with renal insufficiency (RI group, Clcr: 11 +/- 6 ml/min) and in 12 CHD-patients with normal kidney function (control group, Clcr: 88 +/- 22 ml/min) [23].


  1. CT can reduce hospitalization for observation in children with suspected appendicitis. Acosta, R., Crain, E.F., Goldman, H.S. Pediatric radiology. (2005) [Pubmed]
  2. Cefotaxime and desacetyl cefotaxime kinetics in renal impairment. Matzke, G.R., Abraham, P.A., Halstenson, C.E., Keane, W.F. Clin. Pharmacol. Ther. (1985) [Pubmed]
  3. Pharmacokinetics and pharmacodynamics of roxatidine in patients with renal insufficiency. Gladziwa, U., Wagner, S., Sieberth, H.G., Klotz, U. British journal of clinical pharmacology. (1995) [Pubmed]
  4. Effect of Lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies. Cinotti, G.A., Zucchelli, P.C. Nephrol. Dial. Transplant. (2001) [Pubmed]
  5. Disposition kinetics of dibekacin in patients with renal failure and in patients undergoing hemodialysis. Arancibia, A., Baillarie, D., Bravo, M., Chávez, J. International journal of clinical pharmacology and therapeutics. (1995) [Pubmed]
  6. Chymotrypsin C (caldecrin) stimulates autoactivation of human cationic trypsinogen. Nemoda, Z., Sahin-Tóth, M. J. Biol. Chem. (2006) [Pubmed]
  7. Disposition and safety of omapatrilat in subjects with renal impairment. Sica, D.A., Liao, W., Gehr, T.W., Khan, S., Jemal, M., Delaney, C.L., Ferreira, I.M., Malhotra, B.K. Clin. Pharmacol. Ther. (2000) [Pubmed]
  8. Imipenem pharmacokinetics in patients with burns. Boucher, B.A., Hickerson, W.L., Kuhl, D.A., Bombassaro, A.M., Jaresko, G.S. Clin. Pharmacol. Ther. (1990) [Pubmed]
  9. Nizatidine, and H2-receptor antagonist: disposition and safety in the elderly. Callaghan, J.T., Rubin, A., Knadler, M.P., Bergstrom, R.F. Journal of clinical pharmacology. (1987) [Pubmed]
  10. Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function. Takabatake, T., Ohta, H., Maekawa, M., Yamamoto, Y., Ishida, Y., Hara, H., Nakamura, S., Ushiogi, Y., Kawabata, M., Hashimoto, N. Eur. J. Clin. Pharmacol. (1985) [Pubmed]
  11. Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD. Kowalsky, S.F., Echols, M., Schwartz, M.T., Bailie, G.R., McCormick, E. Clin. Nephrol. (1993) [Pubmed]
  12. Influence of renal failure on cytochrome P450 activity in hypertensive patients using a "cocktail" of antipyrine and nifedipine. Lanchote, V.L., Ping, W.C., Santos, S.R. Eur. J. Clin. Pharmacol. (1996) [Pubmed]
  13. Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects. Shah, A., Lettieri, J., Blum, R., Millikin, S., Sica, D., Heller, A.H. J. Antimicrob. Chemother. (1996) [Pubmed]
  14. Bisphosphonate whole body retention test: relations to bone mineralization rate, renal function and bone mineral content in osteoporosis and metabolic bone disorders. Mosekilde, L., Hasling, C., Tågehøj Jensen, P.C., Tågehøj Jensen, F. Eur. J. Clin. Invest. (1987) [Pubmed]
  15. Saluretic effect of the loop diuretic torasemide in chronic renal failure. Interdependence of electrolyte excretion. Knauf, H., Mutschler, E. Eur. J. Clin. Pharmacol. (1990) [Pubmed]
  16. Renal clearance of digoxin in man after sodium loading or furosemide treatment. Naafs, M.A., van der Hoek, C., Schopman, W., van Duin, S., Koorevaar, G., Silberbusch, J. Eur. J. Clin. Pharmacol. (1983) [Pubmed]
  17. The relation between type of renal disease and renal drug clearance in children. Paap, C.M., Nahata, M.C. Eur. J. Clin. Pharmacol. (1993) [Pubmed]
  18. Ceforanide kinetics in renal insufficiency. Hawkins, S.S., Alford, R.H., Stone, W.J., Smyth, R.D., Pfeffer, M. Clin. Pharmacol. Ther. (1981) [Pubmed]
  19. Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. Kirch, W., Rose, I., Demers, H.G., Leopold, G., Pabst, J., Ohnhaus, E.E. Clinical pharmacokinetics. (1987) [Pubmed]
  20. Plasma pentamidine concentrations vary between individuals with Pneumocystis carinii pneumonia and the drug is actively secreted by the kidney. Lidman, C., Bronner, U., Gustafsson, L.L., Rombo, L. J. Antimicrob. Chemother. (1994) [Pubmed]
  21. Chymotrypsin C (caldecrin) promotes degradation of human cationic trypsin: identity with Rinderknecht's enzyme Y. Szmola, R., Sahin-Tóth, M. Proc. Natl. Acad. Sci. U.S.A. (2007) [Pubmed]
  22. The value of contrast-enhanced helical CT scan with rectal contrast enema in the diagnosis of acute appendicitis. Naffaa, L.N., Ishak, G.E., Haddad, M.C. Clinical imaging. (2005) [Pubmed]
  23. Pharmacokinetics of linsidomine (SIN 1) after single and multiple intravenous short infusions in patients with renal insufficiency. Sennesael, J., Verbeelen, D., Degré, S., Unger, P., Stolear, J.C., Ostrowski, J., von Hattingberg, H.M., Gaertner, W. International journal of clinical pharmacology, therapy, and toxicology. (1993) [Pubmed]
WikiGenes - Universities